Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma

International Journal of Cancer

Volumn 138, Issue 11, 2016, Pages 2732-2744

  Ghosh, Amit ^a   Ghosh, Alip ^a   Datta, Somenath ^a   Dasgupta, Debanjali ^a   Das, Soumyajit ^a   Ray, Sukanta ^a   Gupta, Subash ^b   Datta, Simanti ^a   Chowdhury, Abhijit ^a   Chatterjee, Raghunath ^c   Mohapatra, Saroj Kant ^d   Banerjee, Soma ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b INDRAPRASTHA APOLLO HOSPITAL   (India)

^c INDIAN STATISTICAL INSTITUTE   (India)

^d NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS   (India)

Author keywords

biomarker; HBV; HCC; hepatitis B virus; hepatocellular carcinoma; MicroRNA; miR 126

Indexed keywords

ALPHA FETOPROTEIN; APC PROTEIN; APC2 PROTEIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CRK LIKE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EARLY GROWTH RESPONSE FACTOR 2; INSULIN RECEPTOR SUBSTRATE 1; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MICRORNA; MICRORNA 126; MIR 142 3P; UNCLASSIFIED DRUG; MIRN126 MICRORNA, HUMAN; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; MALE; PATHOGENICITY; PATHOLOGY;

ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS;

EID: 84958568656     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29999     Document Type: Article

References (48)

1. Parkin DM, Pisani P, Ferlay J., Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Bosch FX, Ribes J, Cléries R, et al,. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
3. McMahon BJ., The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24: 17-21.
4. Sarbah SA, Gramlich T, Younoszai A, et al,. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 2004; 49: 850-3.
5. Subrat KA., Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol 2014; 4:3.
6. Zhu K, Dai Z, Zhou J., Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res 2013; 1: 10
7. McMahon BJ, Bulkow L, Harpster A, et al,. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842-6.
8. Sherman M, Peltekian KM, Lee C., Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-8.
9. Sherman M., Surveillance for hepatocellular carcinoma. Semin Oncol 2001; 28: 450-9.
10. Daniele B, Bencivenga A, Megna AS, et al,. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127: S108-12.
11. Rapaccini GL, Pompili M, Caturelli E, et al,. Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int 2004; 24: 124-30.
12. Schultz NA, Dehlendorff C, Jensen BV, et al,. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014; 311: 392-404.
13. Jeffrey SS., Cancer biomarker profiling with microRNAs. Nat Biotechnol 2008; 26: 400-1.
14. Qi P, Cheng SQ, Wang H, et al,. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6: e28486
15. Giray BG, Emekdas G, Tezcan S, et al,. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep 2014; 41: 4513-9.
16. Köberle V, Kronenberger B, Pleli T, et al,. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013; 49: 3442-9.
17. Pigati L, Yaddanapudi SC, Iyengar R, et al,. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010; 5: e13515
18. Pritchard CC, Kroh E, Wood B, et al,. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012; 5: 492-7.
19. Datta S, Ghosh A, Dasgupta D, et al,. Novel point and combo-mutations in the genome of hepatitis B virus-genotype D: characterization and impact on liver disease progression to hepatocellular carcinoma. PloS One 2014; 9: e110012
20. Shwetha S, Gouthamchandra K, Chandra M, et al,. Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep 2013; 3: 1555
21. Kelly BD, Miller N, Sweeney KJ, et al,. A Circulating microRNA signature as a biomarker for prostate cancer in a high risk group. KJ, Durkan GC, Rogers E, Walsh K, Kerin MJ. J Clin Med 2015 7; 4 (7): 1369-79.
22. Mishra S, Srivastava AK, Suman S, Kumar V, et al,. Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer Lett 2015.pii: S0304-3835(15)00514-5.
23. Tan Y, Ge G, Pan T, et al,. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One 2014; 9: e107986.
24. Silver HK, Deneault J, Gold P, et al,. The detection of alpha 1-fetoprotein in patients with viral hepatitis. Cancer Res 1974; 34: 244-7.
25. Debruyne EN, Delanghe JR., Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. ClinChimActa 2008; 395: 19-26.
26. Volk ML, Hernandez JC, Su GL, et al,. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007; 3: 79-87.
27. Cortez MA, Bueso-Ramos C, Ferdin J, et al,. MicroRNAs in body fluids-The mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-77.
28. Wang Y, Gao X, Wei F, et al,. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 2014; 533: 389-97.
29. Li J, Wang Y, Yu W, et al,. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011; 406: 70-3.
30. Zhangn ZQ, Meng H, Wang N, et al,. Serum microRNA-143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol 2014; 9: 135.
31. Lin RJ, Xiao DW, Liao LD, et al,. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J Surg Oncol 2012; 105: 175-82.
32. Zhang T, Li L, Shang Q, et al,. Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals. Biochem Biophys Res Commun 2015; 463: 60-3.
33. Wang P, Yang D, Zhang H, et al,. Early detection of lung cancer in serum by a panel of MicroRNA biomarkers. Clin Lung Cancer 2015; 16: 313.
34. Jiang Y, Wang HY, Li Y, et al,. Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases. Sci Rep 2014; 4: 5026.
35. Bu J, Li H, Li XY, et al,. Prognostic role of MicroRNA-126 for survival in malignant tumors: a systematic review and meta-analysis. Dis Markers 2015;2015:11.
36. Tomimaru Y, Eguchi H, Nagano H, et al,. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012; 56: 167-75.
37. Aqeilan RI, Calin GA, Croce CM., miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010; 17: 215-20.
38. Riad SE, El-Ekiaby N, Mekky RY, et al,. Expression signature of microRNA-155 in hepatitis C virus genotype 4 infection. Biomed Rep 2015; 3: 93-97.
39. Sun Y, Bai Y, Zhang F, et al,. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. BiochemBiophys Res Commun 2010; 391: 1483-9.
40. Feng R, Chen X, Yu Y, et al,. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 2010; 298: 50-63.
41. Jia AY, Castillo-Martin M, Bonal DM, et al,. MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer 2014; 110: 2945-54.
42. Luo JH, Ren B, Keryanov S, et al,. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006; 44: 1012-24.
43. Gortat A, Sancho M, Mondragón L, et al,. Apaf1 inhibition promotes cell recovery from apoptosis. Protein Cell 2015; 6 (11): 833-43.
44. Tang B, Li Y, Qi G, et al,. Clinicopathological significance of CDKN2A promoter hypermethylation frequency with pancreatic cancer. Sci Rep 2015; 5: 13563.
45. Ying X, Li-ya Q, Feng Z, et al,. MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression. Biomed Pharmacother 2015; 71: 64-9.
46. Zhang ZS, Yang DY, Fu YB, et al,. Knockdown of CkrL by shRNA deteriorates hypoxia/reoxygenation-induced H9C2 cardiomyocyte apoptosis and survival inhibition Via Bax and downregulation of P-Erk1/2. Cell Biochem Funct 2015; 33: 80-8.
47. Lagrange B, Martin RZ, Droin N, et al,. A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages. Biochim Biophys Acta 2013; 1833: 1936-46.
48. Chai S, Tong M, Ng KY, et al,. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget 2014; 5: 5725-35.